Azenta awarded Martin William E. III 15,272 shares, with the transaction priced at $0 per share. The award represented about 46.2% of his resulting 33,062-share holding, giving investors a precise view of the executive’s post-transaction Azenta Equity position and the size of the grant relative to it.
Key Highlights
- The shares were awarded at $0 per share.
- The filing reported transaction code A for the award.
- The award represented about 46.2% of Martin William E. III’s resulting holding.
Azenta, Inc. (NASDAQ: AZTA) awarded 15,272 shares to Martin William E. III on September 14, 2026. The filing reported the award at $0 per share and listed transaction code A.
$0-Per-Share Award Recorded
The transaction carried a price of $0 per share. Azenta identifies Martin William E. III as President Multiomics. The filing lists transaction code A for the award. The award involved 15,272 Azenta shares.
Resulting Holding Reaches 33,062 Shares
Following the transaction, Martin William E. III held 33,062 shares of Azenta. The award represented about 46.2% of that resulting holding. Transaction code A denotes an award, grant, or other Acquisition from the company.
FAQs
Q: How many Azenta shares did Martin William E. III receive?
A: Martin William E. III was awarded 15,272 Azenta shares. The award was recorded on September 14, 2026, and carried a price of $0 per share.
Q: What was Martin William E. III’s resulting Azenta shareholding?
A: Following the transaction, Martin William E. III owned 33,062 Azenta shares. The filing states that the 15,272-share award represented about 46.2% of his resulting Azenta shareholding.
Q: What transaction code did the filing report?
A: The filing reported transaction code A for the Azenta award. It also states that Martin William E. III was awarded 15,272 shares.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.